TAC Health Card | Parkinson’s disease target validation
T layer — Mechanistic evidence
Status: STRONG
LRRK2 is implicated in kinase signaling, vesicular trafficking, lysosomal biology, and neuronal homeostasis.
Mechanistic models support a plausible role for LRRK2 dysregulation in Parkinson’s disease pathogenesis, particularly in mutation-carrying subgroups.
Preclinical work has generated a coherent rationale for therapeutic inhibition or modulation.
Φ layer — Genetic evidence
Status: STRONG
Human genetics provide strong support for LRRK2 relevance in Parkinson’s disease.
Pathogenic variants in LRRK2 are among the clearest inherited contributors to familial Parkinsonism, supporting a causal role in disease biology.
This makes LRRK2 one of the more genetically grounded targets in neurodegeneration.
Σ layer — Clinical evidence
Status: PARTIAL / EMERGING
Clinical translation remains incomplete.
Although target interest is high and multiple programs are active, definitive patient-level validation remains limited.
Current evidence supports continued development, but not yet full translational closure.
Alignment topology
TΦΣ
Pattern: genetics-supported frontier topology
Decision interpretation
LRRK2 represents a high-potential target with strong mechanistic and genetic support, but incomplete clinical confirmation.
Cross-layer evidence alignment indicates meaningful translational promise, while preserving uncertainty at the clinical layer.
This is a classic case of frontier validation rather than fully mature target de-risking.
Why this case matters
LRRK2 is a useful example of how TAC Topology distinguishes between strong scientific prioritization and true decision maturity.
It shows that even high-confidence targets may remain in an intermediate state until clinical evidence resolves translational uncertainty.